GlassScriptPhysician profile
John R Durant
NPI 1790717858
$4,678.33
in general payments reported to CMS, 2019-2025
32 companies · $419 in 2025
The $419 reported for 2025 was more than what 81% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $501 · 2020: $599 · 2021: $795 · 2022: $777 · 2023: $850 · 2024: $737 · 2025: $419.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,941 · Education: $64.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,940.72 |
| Education | $64.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,083.56 | 2019-2025 | Trelegy Ellipta |
| Abbvie INC. | $975.32 | 2021-2025 | Vraylar, Qulipta |
| Bayer Healthcare Pharmaceuticals INC. | $532.17 | 2022-2025 | |
| Allergan, INC. | $296.04 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $249.42 | 2019-2023 | Farxiga, Fasenra |
| Pfizer INC. | $184.08 | 2019-2024 | |
| Novo Nordisk INC | $169.44 | 2020-2025 | Ozempic, Rybelsus |
| Otsuka America Pharmaceutical, INC. | $136.22 | 2019-2024 | Rexulti |
| Biohaven Pharmaceutical Holding Company LTD. | $86.10 | 2022 | |
| Amgen INC. | $85.13 | 2019-2025 | Otezla, Repatha |
| Indivior INC. | $77.41 | 2019 | |
| Sunovion Pharmaceuticals INC. | $69.99 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $69.13 | 2019-2022 | |
| Astellas Pharma US INC | $64.99 | 2024 | |
| Teva Pharmaceuticals USA, INC. | $61.76 | 2019-2023 | Austedo |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $59.19 | 2023-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $56.00 | 2023-2025 | Ingrezza |
| Mylan Specialty L.P. | $51.77 | 2020-2024 | Yupelri |
| Axsome Therapeutics, INC. | $48.79 | 2023-2024 | Auvelity |
| Janssen Pharmaceuticals, INC | $46.93 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $39.00 | 2022-2024 | Xifaxan |
| Biohaven Pharmaceuticals, INC. | $30.35 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.21 | 2020 | |
| Lundbeck LLC | $25.82 | 2024 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $23.41 | 2021 | |
| Shire North American Group INC | $22.97 | 2019 | |
| Inspire Medical Systems, INC. | $22.40 | 2024 | Inspire |
| Edwards Lifesciences Corporation | $22.14 | 2024 | |
| Xeris Pharmaceuticals, INC. | $18.17 | 2024 | Gvoke Hypopen |
| Dexcom, INC. | $17.01 | 2023 | Dexcom G6 Transmitter |
| Philips North America LLC | $13.89 | 2024 | (Cm9) Amb Mon & Diag Und |
| Lilly USA, LLC | $11.52 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Durant listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.